CSIMarket Company Name, Ticker, Customers, else..
 
Argenx se  (NASDAQ: ARGX)
Other Ticker:  
 
 
Price: $613.0400 $-6.93 -1.118%
Day's High: $621.565 Week Perf: 1.34 %
Day's Low: $ 612.10 30 Day Perf: -4.23 %
Volume (M): 177 52 Wk High: $ 678.21
Volume (M$): $ 108,324 52 Wk Avg: $521.64
Open: $617.00 52 Wk Low: $352.77



 Market Capitalization (Millions $) 35,047
 Shares Outstanding (Millions) 57
 Employees 700
 Revenues (TTM) (Millions $) 2,495
 Net Income (TTM) (Millions $) -295
 Cash Flow (TTM) (Millions $) 801
 Capital Exp. (TTM) (Millions $) 1

Argenx Se
Argenx is a biopharmaceutical company that focuses on the discovery and development of antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company utilizes its proprietary antibody discovery platforms to identify and develop unique therapeutic candidates. Argenx's lead product, efgartigimod (ARGX-113), is being developed for various autoimmune diseases, including myasthenia gravis and immune thrombocytopenia. The company also has a pipeline of other investigational drugs targeting various indications. Argenx operates globally and collaborates with other pharmaceutical companies to accelerate the development and commercialization of its therapies.


   Company Address: Laarderhoogtweg 25 Amsterdam 9052
   Company Phone Number: 10 70 38 441   Stock Exchange / Ticker: NASDAQ ARGX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        0.42% 
BIIB        1.39% 
EXEL        1.45% 
GILD   -5%    
ITOS   -5.94%    
SGEN        4.77% 
• View Complete Report
   



Stocks on the Move

Navigating Market Currents Argenx SEs Strategic Growth Amidst Trading Signals

Published Wed, Aug 21 2024 10:56 AM UTC

In a month marked by dynamic market fluctuations, health care investors and industry stakeholders are closely monitoring leading biopharmaceutical companies like Argenx SE. As we delve into the latest financial and operational highlights, it becomes evident that the trajectory of Argenx SE which specializes in immunology treatments is being shaped by both strategic initiativ...
Stocks on the Move

Argenx SE An Overview of Recent Analyst Sentiments and Promising Developments in the Healthcare Sector

Published Fri, Jul 12 2024 11:39 AM UTC

In recent news, two analysts have expressed their bullish sentiments towards Arcus Biosciences (RCUS) and Argenx SE (ARGX). This article aims to delve into the various news updates surrounding Argenx SE, an emerging genetic medicine company, and explore the recent market trends and developments in the healthcare sector. Additionally, we will provide an overview of Argenx SE ...
Stocks on the Move

J&J Poses a Strong Challenge to Argenxs Vyvgart with Positive Phase III Data

Published Tue, Jul 2 2024 4:30 PM UTC

In recent news, Johnson & Johnson (J&J) has emerged as a formidable competitor to Argenx s Vyvgart with promising results from its Phase III clinical trial for nipocalimab. The data showcases the antibody s effectiveness in improving symptoms associated with myasthenia gravis, a chronic autoimmune neuromuscular disease. J&J s decision to target a broader patient population c...
Stocks on the Move

Argenx Se Expands Autoimmune Pipeline and Achieves FDA Approval for Vyvgart Hytrulo for CIDP

Published Thu, Jun 27 2024 12:27 PM UTC

In the field of immunology, Argenx SE has been making significant strides in addressing severe autoimmune diseases. This article highlights recent developments in Argenx s multifocal motor neuropathy data presentation, the surge in stock prices, and the FDA s approval of Vyvgart Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). These adva...
Argenx Se

Argenx Se Shines Bright: Fourth Quarter 2023 Revenue Soars to $2.49 Billion2.

In a world of uncertainty, one sector has managed to rise above the challenges and come out shining. Argenx Ses, a leading player in the Biotechnology & Pharmaceuticals industry, has just announced some truly remarkable financial results that have set the stock market abuzz.
The company's revenue has soared by an astounding 191.457% year on year, reaching an impressive $2.49 billion in the October to December 31, 2023 span. This remarkable achievement is even more remarkable when you consider the difficult times faced by many other companies in the industry, which have seen receding orders and a fading top-line. Argenx Ses, on the other hand, has managed to stand tall and prove its resilience.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com